WuXi Biologics as part of its global expansion effort has announced another successful closure of another lease agreement of another facility. It has already closed two major lease agreements just before that.
They have signed a 10-year lease agreement to occupy a 66,000-square-foot clinical manufacturing facility in Cranbury, New Jersey, becoming its third facility in the United States, a contract manufacturing and development organization.
The new facility expects to be employing over 100 employees and to be fully operational by the end of 2020. The new facility will include 6,000 liters of bioreactor space along with process development and quality control labs and other supporting functions.
In May, they closed a deal to build its first biologics facility in the United States at a 46-acre master-planned manufacturing hub in Worcester, Massachusetts. The two-story, 107,000-square-foot facility will cost $60 million and employ 150 when it is fully operational in 2022, WuXi said in a release.
Chief Executive Officer of WuXi Biologics, Chris Chen said that the company targeted the greater Boston area for its talented workforce and impressive biotech network.
In May, WuXi added that big investment with a lease agreement for a 33,000-square-foot process development lab in King of Prussia, Pennsylvania.
WuXi Biologics also added that they have expansion plans in Germany through a take-over of a Bayer plant in Leverkusen, to be used as a facility for its own purposes but also to provide backup supply for Bayer’s hemophilia drug Kovaltry if required.